" class="no-js "lang="en-US"> University of Zurich - Medtech Alert
Thursday, September 18, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
University of Zurich | Pharmtech Focus

University of Zurich

About University of Zurich

University of Zurich

The University of Zurich is a public research university located in the city of Zürich, Switzerland. It is the largest university in Switzerland, with its 28,000 enrolled students. It was founded in 1833 from the existing colleges of theology, law, medicine which go back to 1525, and a new faculty of philosophy.

Related Story

Clinical Trials

 HMNC Brain Health and Develco Pharma Announce Promising Preliminary Results in Treatment-resistant Depression (TRD) | Pharmtech Focus

HMNC Brain Health and Develco Pharma Announce Promising Preliminary Results in Treatment-resistant Depression (TRD)

April 1 2022

HMNC Brain Health (“HMNC” or the “Company”), a global clinical stage biopharmaceutical company pioneering the […]